Journal of Cancer and Medical Imaging

Education

• Completed a medical degree (Medicine / MD) in the Netherlands
• Trained as a specialist in Radiation Oncology
• Undertook research training (PhD-level work or doctoral research) in the field of cancer treatment and radiation therapy during her early career

Biography

Monique C. de Jong is a Dutch medical doctor and specialist in radiation oncology, working at the Netherlands Cancer Institute (NKI-AVL), one of Europe’s leading cancer research and treatment centers.

She completed her medical degree in the Netherlands and subsequently trained as a radiation oncologist. During her professional development, she also engaged in clinical research focused on improving cancer treatment outcomes, particularly through radiotherapy and combined treatment approaches.

Medical and research career

In her role at the Netherlands Cancer Institute, she:

• Treats patients with different types of cancer, including lung and gastrointestinal cancers
• Contributes to clinical trials aimed at improving radiation therapy techniques
• Works on integrating radiotherapy with systemic treatments such as chemotherapy and immunotherapy
• Participates in academic research and multidisciplinary oncology teams

Focus areas

Her clinical and scientific interests include:

• Lung cancer treatment
• Esophageal cancer
• Hematological (blood-related) malignancies
• Optimization of radiation dose and treatment response

Main research interests

• Radiation oncology optimization: improving how radiotherapy is delivered to increase effectiveness and reduce side effects
• Lung cancer treatment: studying better radiation schedules and combinations with other therapies
• Esophageal cancer research: improving outcomes in locally advanced disease using multimodal treatment
• Hematological malignancies: role of radiotherapy in blood-related cancers
• Combined therapies: integrating radiotherapy with chemotherapy and immunotherapy
• Clinical trials: designing and participating in studies that test new treatment approaches in real patients
• Treatment response prediction: identifying factors that help predict how tumors respond to radiation

Clinical research & trials

• Actively involved in clinical trials at the Netherlands Cancer Institute
• Designs and participates in studies evaluating new radiotherapy techniques
• Works on combined modality trials, integrating radiotherapy with chemotherapy and immunotherapy
• Contributes to research on treatment sequencing, dosing, and response outcomes

Academic contributions

• Co-author of peer-reviewed scientific publications in oncology and radiation therapy
• Contributes to multidisciplinary cancer research projects involving oncologists, physicists, and biologists
• Participates in research focused on lung cancer, esophageal cancer, and hematologic malignancies

Professional collaboration & teaching

• Works in multidisciplinary tumor boards, helping shape treatment strategies based on evidence
• Engages in training and mentoring of medical residents and oncology fellows
• Contributes to knowledge sharing within national and international oncology networks

Monique C. de Jong has published scientific work mainly in the field of radiation oncology and clinical cancer research, but there is no single short “official list” of all her publications because her work is spread across many collaborative oncology studies.

Publication themes (what her papers focus on)

Her peer-reviewed publications generally fall into these areas:

• Lung cancer radiotherapy
  • Outcomes of stereotactic and conventional radiotherapy
  • Dose optimization and treatment planning
• Esophageal cancer
  • Combined chemoradiation strategies
  • Predictors of treatment response and survival
• Hematological malignancies
  • Role of radiotherapy in lymphoma and related cancers
• Combined modality treatments
  • Integration of radiotherapy with chemotherapy or immunotherapy
  • Timing and sequencing of multimodal cancer therapy
• Clinical trials and outcome studies
  • Real-world patient outcomes from institutional trials at the Netherlands Cancer Institute
  • Toxicity and quality-of-life analyses after treatment